In vitro testing revealed synergistic effect of combined hydroxychloroquine (HCQ) and azithromycin (AZM) on SARS-CoV-2
In a French study, researchers isolated SARS-CoV-2-IHUMI-3, a strain of the coronavirus, and tested various combinations of HCQ and AZM with Vero E6 cells.
- Isolation of the viral strain and viral stock
- In vitro testing procedure
- In vitro testing results of combined HCQ and AZM on viral strain
- Discussion of in vitro testing results of combined HCQ and AZM on viral strain
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
In a French open-label non-randomized clinical trial, more patients treated with hydroxychloroquine+azithromycin tested negative for COVID-19 by day 6 after inclusion in study compared to a control group
In vitro testing revealed synergistic effect of combined hydroxychloroquine (HCQ) and azithromycin (AZM) on SARS-CoV-2
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
French open-label non-randomized clinical trial in support of treating COVID-19 patients with HCQ
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
In vitro testing revealed synergistic effect of combined hydroxychloroquine (HCQ) and azithromycin (AZM) on SARS-CoV-2